Physician profile
Ira Strauss
NPI 1225006927
$1,537.36
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $182 · 2021: $567 · 2022: $47.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $281.22 | 2020-2021 | |
| Amgen INC. | $228.45 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $216.87 | 2019-2021 | |
| Vifor Pharma, INC. | $143.56 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $142.65 | 2019-2021 | |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Akebia Therapeutics INC | $114.17 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.29 | 2021 | |
| Opko Pharmaceuticals, LLC | $73.93 | 2019-2021 | |
| Horizon Therapeutics Plc | $41.55 | 2021 | |
| Baxter Healthcare | $26.00 | 2022 | |
| Bard Peripheral Vascular, INC. | $21.78 | 2022 | |
| Mallinckrodt Enterprises LLC | $11.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Strauss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.